Literature DB >> 1500499

Primary humoral antibody response to Coxiella burnetii, the causative agent of Q fever.

D Guigno1, B Coupland, E G Smith, I D Farrell, U Desselberger, E O Caul.   

Abstract

Of 147 patients with acute Q fever diagnosed during a major outbreak in Birmingham, England, in early summer 1989, 41 provided sets of sera which allowed us to make a detailed analysis of the primary humoral immune response. Antibody titers specific for Coxiella burnetii were measured by the complement fixation test and by an immunoglobulin M (IgM)- and IgG-specific indirect immunofluorescence test. The relative avidity of specific IgGs was determined by the indirect immunofluorescence test with and without treatment of antigen-antibody complexes with 8 M urea. The IgG subclass responses after primary infection and their avidities were also determined for a limited number of paired serum specimens. Specific IgM titers persisted for more than 6 months in the majority of cases and were therefore not a sufficient criterion for the diagnosis of recent infection. However, for serial samples the antibody titer ratios (IgG/IgM) and the ratios (IgG titer with treatment/IgG titer without treatment) that indicated relative avidity changed significantly, depending on the time postinfection. Within the IgG class, the C. burnetii-specific antibody response over time was almost exclusively represented by subclass 1 molecules, which thus showed affinity maturation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500499      PMCID: PMC265423          DOI: 10.1128/jcm.30.8.1958-1967.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  [Description of a method for the determination of the number and quality of influenza virus antibody molecules by means of equilibrium centrifugation (author's transl)].

Authors:  D Lubach
Journal:  Zentralbl Bakteriol Orig A       Date:  1975

2.  Stepwise intraclonal maturation of antibody affinity through somatic hypermutation.

Authors:  C Kocks; K Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

3.  Coxiella burnetii infection (Q fever).

Authors:  D Behymer; H P Riemann
Journal:  J Am Vet Med Assoc       Date:  1989-03-15       Impact factor: 1.936

4.  Q fever in an urban area.

Authors:  M M Salmon; B Howells; E J Glencross; A D Evans; S R Palmer
Journal:  Lancet       Date:  1982-05-01       Impact factor: 79.321

5.  Q fever.

Authors:  A M Geddes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-01

6.  Q fever pneumonia associated with exposure to wild rabbits.

Authors:  T J Marrie; W F Schlech; J C Williams; L Yates
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

7.  Specific IgG subclass antibody in rubella virus infections.

Authors:  H I Thomas; P Morgan-Capner
Journal:  Epidemiol Infect       Date:  1988-06       Impact factor: 2.451

8.  Immunoglobulin responses in acute Q fever.

Authors:  G Dupuis; O Péter; M Peacock; W Burgdorfer; E Haller
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

9.  The persistence of complement-fixing antibodies to Q-fever (Coxiella burneti) after infection.

Authors:  A M Murphy; P R Field
Journal:  Med J Aust       Date:  1970-06-06       Impact factor: 7.738

10.  Description of a technique for the determination of the concentration and quality of rubella virus antibody molecules and experience with testing sera from humans with recent and past rubella infection.

Authors:  G Hoppe; J Drescher
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

View more
  21 in total

1.  Q fever pneumonia in children in Japan.

Authors:  H To; N Kako; G Q Zhang; H Otsuka; M Ogawa; O Ochiai; S V Nguyen; T Yamaguchi; H Fukushi; N Nagaoka; M Akiyama; K Amano; K Hirai
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

Review 2.  Diagnosis of Q fever.

Authors:  P E Fournier; T J Marrie; D Raoult
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

3.  Clinical evaluation of a new PCR assay for detection of Coxiella burnetii in human serum samples.

Authors:  G Q Zhang; S V Nguyen; H To; M Ogawa; A Hotta; T Yamaguchi; H J Kim; H Fukushi; K Hirai
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

4.  Rapid method for detection of Coxiella burnetii antibodies using high-density particle agglutination.

Authors:  S V Nguyen; H Otsuka; G Q Zhang; H To; T Yamaguchi; H Fukushi; A Noma; K Hirai
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

5.  Reliability of four methods for the diagnosis of acute infection by Epstein-Barr virus.

Authors:  J Gutiérrez; M Rodríguez; C Maroto; G Piédrola
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

6.  Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus.

Authors:  J J Gray; C Cunliffe; J Ball; D Y Graham; U Desselberger; M K Estes
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

7.  Importance of Q fever in community acquired pneumonia.

Authors:  M Goyette; J Bouchard; A Poirier; E Morrier; H Artsob; F Corbeil
Journal:  Can J Infect Dis       Date:  1996-11

8.  Validation of an enzyme immunoassay for serodiagnosis of acute Q fever.

Authors:  D Waag; J Chulay; T Marrie; M England; J Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

9.  Increases in the levels of Coxiella burnetii-specific immunoglobulin G1 and G3 antibodies in acute Q fever and chronic Q fever.

Authors:  C Capo; I Iorgulescu; M Mutillod; J L Mege; D Raoult
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

10.  Role of immunoglobulin G subclasses in Q fever.

Authors:  M T Camacho; I Outschoorn; A Tellez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.